Evidence map›Paper›PMID 34409373›Full record

ArticleJAAD international2021

Societal impact for patients with psoriasis: A nationwide Swedish register study.

Henrike Häbel, Björn Wettermark, David Hägg, Reginald Villacorta, E Christina M Wennerström, Marie Linder

Open access · goldAbstract read
In one paragraph

Article in JAAD international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Henrike HäbelUnit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Björn WettermarkDepartment of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden.
David HäggCentre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Reginald VillacortaJanssen Pharmaceuticals, Brunnswick, New Jersey.
E Christina M WennerströmJanssen-Cilag, Solna, Sweden.
Marie LinderCentre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEJanssen (United States) · USStatens Serum Institut · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPsoriasis is an immune-mediated chronic inflammatory disease having a significant negative health impact. Psoriasis has societal impact; loss of productivity has been estimated at approximately 10% and it may influence the patient's financial status. Relationships between quality of life, disease severity, and cost of care need exploration. Understanding the disease burden is important for health policy and research allocation. Few studies address the research gaps in socioeconomics, comorbidity, and medication use.

objectiveObserving differences in education, income, employment status, marital status, health care consumption, and drug utilization between patients with psoriasis and matched controls.

methodsCohort study following socioeconomics and health care consumption for all psoriasis patients from the Swedish patient register. All individuals with a first diagnosis of psoriasis in outpatient or inpatient care from 2002 to 2013 were followed until death, emigration, or end of the study.

resultsOverall, 109,803 patients were included (mean age 51.2 years, 53% women) and matched with 1.08 million controls. The levels of education and income were similar, but the proportion employed was significantly lower for patients with psoriasis. There was a tendency for fewer patients with psoriasis to be married. LIMITATIONS: Generalizability, lack of primary care diagnoses, and lack of early treatments (available from 2005).

conclusionUnderstanding of the socioeconomic impact of psoriasis is extended by showing reductions in employment.

Indexed as

disease burdendrug utilizationICD, International Classification of DiseasesNPR, National Patient RegisterPDR, Swedish Prescribed Drug RegisterpsoriasisSEK, Swedish crownssocietal impactTPR, Total Population Register

Identifiers

PMID34409373
PMCPMC8362274
OpenAlexW3147852364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.